Claims for Patent: 10,047,117

Summary for Patent: 10,047,117

Title:	Preparation and uses of obeticholic acid
Abstract:	The present invention relates to obeticholic acid: ##STR00001## or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing HDL cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis. The present invention also relates to processes for the synthesis of obeticholic acid.
Inventor(s):	Steiner; Andre (Raubling, DE), Waenerlund Poulsen; Heidi (Koge, DK), Jolibois; Emilie (Cambridge, GB), Rewolinski; Melissa (San Diego, CA), Gross; Ralf (Raubling, DE), Sharp; Emma (Cambridge, GB), Dubas-Fisher; Fiona (Cambridge, GB), Eberlin; Alex (Cambridge, GB)
Assignee:	Intercept Pharmaceuticals, Inc. (New York, NY)
Application Number:	14/947,658
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,047,117
Patent Claims:	1. A method of treating an FXR mediated disease or condition in a subject comprising administering to the subject a pharmaceutical formulation comprising an effective amount of a substantially pure solid form of obeticholic acid, wherein the solid form of obeticholic acid comprises less than 1% of chenodeoxycholic acid, and wherein the formulation comprises about 1 mg to about 30 mg of obeticholic acid. 2. The method of claim 1, wherein the FXR mediated disease or condition is selected from biliary atresia, cholestatic liver disease, chronic liver disease, nonalcoholic steatohepatitis, hepatitis C infection, alcoholic liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, liver damage due to progressive fibrosis, liver fibrosis, and cardiovascular diseases including atherosclerosis, arteriosclerosis, hypercholesterolemia, and hyperlipidemia. 3. The method of claim 2, wherein the FXR mediated disease or condition is cholestatic liver disease. 4. The method of claim 2, wherein the FXR mediated disease or condition is chronic liver disease. 5. The method of claim 2, wherein the FXR mediated disease or condition is nonalcoholic steatohepatitis. 6. The method of claim 2, wherein the FXR mediated disease or condition is primary biliary cirrhosis. 7. The method of claim 2, wherein the FXR mediated disease or condition is liver fibrosis. 8. The method of claim 1, wherein the solid form of obeticholic acid is Form 1 and wherein the solid form of obeticholic acid Form 1 is the non-crystalline form. 9. The method of claim 1, wherein the solid form of obeticholic acid comprises no more than 0.5% of chenodeoxycholic acid. 10. The method of claim 1, wherein the solid form of obeticholic acid comprises not more than 0.15% of 6.beta.-ethylchenodeoxycholic acid. 11. The method of claim 1, wherein the solid form of obeticholic acid comprises not more than 0.15% of 3.alpha.(3.alpha.,7.alpha.-dihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oyl- oxy)-7.alpha.-hydroxy-6.alpha.-ethyl-5.beta.cholan-24-oic acid. 12. The method of claim 1, wherein the solid form of obeticholic acid comprises one or more compounds selected from 6.beta.-ethylchenodeoxycholic acid, chenodeoxycholic acid, and 3.alpha.(3.alpha.,7.alpha.-dihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oyl- oxy)-7.alpha.-hydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid, wherein 6.beta.-ethylchenodeoxycholic acid is present in an amount between 0% and not more than 0.05%, chenodeoxycholic acid is present in an amount between 0% and not more than 0.2%, and 3.alpha.(3.alpha.,7.alpha.-dihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oyl- oxy)-7.alpha.-hydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid is present in an amount between 0% and not more than 0.05%. 13. The method of claim 8, wherein the solid form of obeticholic acid Form 1 is characterized by a glass transition temperature (Tg) of 102 to 112.degree. C.